Damoctocog alfa pegol

Damoctocog alfa pegol (also known as BAY 94-9027) is a recombinant DNA derived, Factor VIII replacement, antihemophilic agent. It is used in the treatment of hemophilia A, a genetic disorder that results in impaired blood clotting.

Mechanism of Action

Damoctocog alfa pegol is a B-domain deleted human factor VIII (FVIII) molecule, to which a single polyethylene glycol (PEG) molecule has been attached. The PEGylation process increases the half-life of the FVIII molecule, allowing for less frequent dosing. The drug binds to the natural coagulation factor VIII in the body, replacing the missing or defective factor VIII in hemophilia A patients, thereby promoting hemostasis and controlling bleeding episodes.

Clinical Use

Damoctocog alfa pegol is indicated for use in adults and children with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes, and perioperative management of bleeding.

Pharmacokinetics

The pharmacokinetics of damoctocog alfa pegol involves a longer half-life and a slower clearance rate compared to unmodified factor VIII. This is due to the PEGylation process, which increases the size of the molecule and reduces its rate of metabolism and excretion.

Side Effects

Common side effects of damoctocog alfa pegol include headache, cough, nausea and fever. Serious side effects may include development of factor VIII inhibitors, which can prevent the medication from working effectively.

Contraindications

Damoctocog alfa pegol is contraindicated in patients who have had life-threatening hypersensitivity reactions to the drug or its components.

See Also

• Hemophilia
• Factor VIII
• Recombinant DNA
• Polyethylene glycol